Suchergebnisse - "Decaux, Olivier"

PubPharm (10)

1

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

enthalten in: The New England journal of medicine | 2021

von Kastritis, E. | Palladini, G. | Minnema, M. | +148

CommentIn: Nat Rev Rheumatol. 2021 Sep;17(9):510. - PMID 34345020

2

Atypical bortezomib-induced neutrophilic dermatosis

enthalten in: Annals of hematology | 2019

von Lescoat, A. | Dupuy, A. | Belhomme, N. | +5

3

Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma

enthalten in: Clinical lymphoma, myeloma & leukemia | 2019

von Caillon, H. | Avet-Loiseau, H. | Attal, M. | +3

4

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

enthalten in: Blood | 2018

von Perrot, A. | Lauwers-Cances, V. | Corre, J. | +37

CommentIn: Blood. 2018 Dec 6;132(23):2424-2425. - PMID 30523123

5

Rare myopathy associated to MGUS, causing heart failure and responding to chemotherapy

enthalten in: Annals of hematology | 2017

von Belhomme, N. | Maamar, A. | Le Gallou, T. | +8

6

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma : the Intergroupe Francophone du Myelome 2009-01 trial

enthalten in: Haematologica | 2015

von Rodon, P. | Hulin, C. | Pegourie, B. | +27

7

Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)

enthalten in: Haematologica | 2014

von Jaccard, A. | Comenzo, R. | Hari, P. | +14

CommentIn: Haematologica. 2014 Sep;99(9):1407-9. - PMID 25176981

8

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma : Intergroupe Francophone du Myélome 2009-02

enthalten in: Blood | 2013

von Leleu, X. | Attal, M. | Arnulf, B. | +26

CommentIn: Blood. 2013 Mar 14;121(11):1926-8. - PMID 23493767

9

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

enthalten in: Blood | 2011

von Moreau, P. | Avet-Loiseau, H. | Facon, T. | +28

10

Inhibition of mTORC1 activity by REDD1 induction in myeloma cells resistant to bortezomib cytotoxicity

enthalten in: Cancer science | 2010

von Decaux, O. | Clément, M. | Magrangeas, F. | +5

1
[1]